ABSTRACT
The aim of this study was to determine the prevalence of musculoskeletal pain and rheumatic diseases in subjects over 18 years of age from the canton of Cuenca, Ecuador. Cross-sectional analytical community-based study was conducted in subjects over 18 years of age using the validated Community-Oriented Program for the Control of Rheumatic Diseases (COPCORD) questionnaire. Random sampling was used. The questionnaire was administered by standardized health workers. Subjects were visited house by house. Subjects positive for musculoskeletal (MSK) pain in the last 7 days and at some point in life were assessed by rheumatologists to confirm the diagnosis. A total of 4877 subjects participated, with an average age of 42.8 (SD 18.8) years of age; 59.7 % were women; 69.7 % lived in urban areas. 32.5 % reported MSK pain in the last 7 days and 45.7 % at some point in life. The prevalence of knee osteoarthritis was 7.4 %, hand osteoarthritis 5.3 %, low back pain 9.3 %, rheumatoid arthritis 0.8 %, fibromyalgia 2 %, gout 0.4 %, and lupus 0.06 %. Subjects from rural areas reported experiencing more MSK pain in the last 7 days and at some point in life, lower income, poorer health-care coverage, and increased physical activity involving repetitive tasks such as lifting weights or cooking with firewood. MSK pain prevalence was high. Osteoarthritis and low back pain were the most common diseases. Age, sex, physical activity, repetitive tasks, living in a rural area, and lack of health-care coverage were found to be associated with MSK pain.
Subject(s)
Musculoskeletal Diseases/epidemiology , Rheumatic Diseases/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Cross-Sectional Studies , Disability Evaluation , Ecuador , Female , Health Surveys , Humans , Male , Middle Aged , Musculoskeletal Pain/epidemiology , Pain Measurement , Prevalence , Sex Factors , Young AdultABSTRACT
Se estudió la eficacia terapéutica y la tolerancia clínica y biológica de la asociación sulfato de glucosamina + condronitin sulfato (grupo c) en comparación con sulfato de glucosamina (grupo A) y condrotin sulfato (grupo B9, en 286 pacientes con artrosis de cadera o de rodilla clínicamente evolutiva. Los tres grupos mostraron mejoría clínica en los controles de 6 y 12 semanas en las variables analizadas, con diferencias estadísticamente significativas a favor de la asociación (grupo C) en la distancia máxima en metros sin dolor al caminar y la evaluación terapéutica global por el paciente al final del tratamiento. La tolerancia fue muy buena en los tres grupos. Se concluye que la asociación sulfato de glucosamina + condrotin sulfato se erige en una terapéutica farmacológica de interés para el tratamiento de pacientes con artrosis.
